Loading stock data…
DXCM
$78.19+1.57 (+2.05%)
After Hours$78.28+0.09 (+0.12%)· Last close Jun 9
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DexCom, Inc. in the Healthcare sector is trading at $78.19 with a market capitalization of $28.1B. Wall Street consensus targets $83.00 (24 analysts), implying a +6.2% move over the next 12 months. The stock is currently 13% below its 52-week high of $89.98, remaining 15.6% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$78.19
Potential Upside
60.1%
Whystock Fair Value$125.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus24 analysts
Mean target$83.00+6.2%
Range$65.00 – $112.00
Fundamentals
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.23
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.47%
Volume
Today's trading volume
4.76M
Recent News
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum
Recent performance snapshot for DexCom (DXCM) With no single headline event driving DexCom (DXCM) recently, investors are watching the stock after a gain of about 21% over the past month and roughly 7% over the past 3 months. See our latest analysis for DexCom. That recent 20.7% 1 month share price return sits against a 9.5% year to date share price gain, while the 1 year total shareholder return is down 15.9%, so recent momentum contrasts with weaker longer term outcomes. If DexCom’s move...
Is DexCom Stock Underperforming the Dow?
DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.
Dexcom buys Nutrisense; Insulet rolls out patch pump update
In the lead-up to the American Diabetes Association’s Scientific Sessions, Dexcom announced an acquisition and Insulet improved the software for its latest patch pump.
Here's Why You Should Retain DexCom Stock in Your Portfolio
DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.